(Q33811481)

29 July 2017

1 reference

title

Advances in psoriasis therapy (English)

1 reference

29 July 2017

Lebwohl M

1

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

18

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

13-9, vii

1 reference

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

[Acute kidney failure during psoriasis therapy with fumaric acid derivatives]

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Photodynamic therapy for psoriasis?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Topical calcipotriene in combination with UVB phototherapy for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Interactions between tazarotene and ultraviolet light

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Topical calcipotriol in the treatment of intertriginous psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Mycophenolate mofetil for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Tazarotene in combination with phototherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Interactions between calcipotriene and ultraviolet light

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Compatibility of calcipotriene with other topical medications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Long-term use of topical calcipotriol in chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Pulse dosing of thioguanine in recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Calcipotriol improves the response of psoriasis to PUVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

6-Thioguanine treatment of psoriasis: experience in 81 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970142-X

7 January 2021

10.1016/S0733-8635(05)70142-X

Identifiers

DOI

1 reference

29 July 2017

1 reference